HPN217 is a BCMA-targeting tri-specific t-cell activating construct (TriTAC) in development for patients with multiple myeloma.
SparkCures ID | 367 |
---|---|
Developed By | Harpoon Therapeutics |
Generic Name | HPN217 |
Treatment Classifications |
|
Treatment Targets |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.